Physician profile

Michael D Clark

Vascular Surgery · Atlanta, GA

NPI 1528028925

$1,387.19

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$396.46

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
W. L. Gore & Associates, INC. $642.43 2019-2023 Gore Tag Thoracic Endoprosthesis
Silk Road Medical, INC. $194.86 2019
Trilliant Surgical LLC. $165.24 2023 Arsenal Ankle 10 Hole 1/3 Tubular Plate
Medical Device Business Services, INC. $124.47 2019
Depuy Synthes Sales INC. $111.26 2022
Avinger INC. $86.90 2019
Si-Bone, INC. $31.11 2021
Abbvie INC. $30.92 2023-2024 Vraylar

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael D Clark

$1,387.19

in general payments reported 2019-2025

Years
2019-2024
Top company
W. L. Gore & Associates, INC.

https://glasscript.com/doctor/23845/michael-d-clark

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.